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In rats injected with an arthropathogenic dose of streptococcal cell wall
fragments, serum hemolytic activity decreased over the first 24 h and was then
elevated from days 2 through 6 after injection. Hemolytic activity was again
elevated at days 26 and 40. Levels of activity of alternative complement pathway,
C3, and factor D were also altered.
We have previously reported that the peptido-
glycan-polysaccharide complex (PG-APS) iso-
lated from cell walls of group A streptococci can
activate the alternative complement pathway
(ACP) in human serum in vitro (7). All of this
activity is associated with the peptidoglycan
moiety (7). It is now apparent from numerous
reports that activation of ACP is a property of
many bacterial species, and several components
of bacterial cells have been identified with this
activity (6, 19). We found that peptidoglycan is
the most potept activator of the ACP (7).
Activated complement components function
as mediators in inflammatory diseases (1, 5, 16)
and are also involved in the regulation of im-
mune responses (10, 14). Therefore, we investi-
gated activation of the ACP induced in vivo by
PG-APS to determine the role of complement
components in the pathogenesis of experimental
arthritis and immune dysfunction in the rat (4,
8).
Veronal-buffered saline (pH 7.5) with 0.1%
gelatin (GVB), GVB plus 40 mM ethylenedia-
minetetraacetate (GVB-EDTA), and GVB plus 8
mM ethylene glycol-bis(,B-aminoethyl ether)-
N,N-tetraacetic acid and 2 mM Mg=+ (GVB-
MgEGTA) have been described (13).
Total serum hemolytic complement activity
was measured as previously described (7), using
sensitized sheep erythrocytes and a kinetic
method devised by Boackle et al. (2).
Activation of the ACP in rat serum was mea-
sured by a modification of the method of Coon-
rod and Jenkins (3). Fresh rabbit erythrocytes
were collected in Alsever solution from New
Zealand white rabbits, and the buffy coat was
removed. The erythrocytes were washed three
times in GVB-MgEGTA and adjusted to a con-
centration of 5 x 108 per ml. A total of 20 gil of
test serum was mixed with 65 ,il of GVB-
MgEGTA. Erythrocytes (20 gil) were then add-
ed, and the mixture was incubated for 20 min at
37°C. To provide an excess of terminal compo-
nents and to ensure that cells which had interact-
ed with the ACP were lysed, 40 Il of normal
pooled rat serum diluted 1:1 with GVB-EDTA
was next added to each tube. The reaction was
allowed to continue at 37°C for another 20 min,
after which the tubes were placed in an ice bath,
and 1 ml of cold GVB-EDTA was added. The
tubes were clarified by centrifugation, and the
optical density was read at 412 nm. Controls
included a cell control containing all reactants
except serum, a control of 100%o lysis (H20), and
a control of lysis by normal pooled rat serum.
Factor 13 activity of rat serum was measured
by the lysis of rabbit erythrocytes in the pres-
ence of factor 13-depleted human serum. Factor
13-depleted human serum was prepared by chro-
matography on BioRex 70 (20). A total of 10 gil
of test serum was mixed with 20 gIl of the factor
13-depleted serum plus 60 gil of GVB-MgEGTA.
Erythrocytes (20 gil) were then added, and the
mixture was incubated for 15 min at 37°C. The
reaction was stopped by the addition of GVB-
EDTA, and the percentage of lysis was deter-
mined by spectrophotometric absorbance at 412
nm. Controls included tubes containing all reac-
tants except test serum, a control of 100% lysis
(H20), and a control of lysis by normal pooled
rat serum.
C3 levels in rat sera were estimated by radial
immunodiffusion (12) with antibody specific for
rat C3 (Cappel Laboratories, Cochranville, Pa.).
Purification of cell wall fragments (PG-APS)
from group A streptococcal cells has been de-
scribed (7, 8). Female Sprague-Dawley rats
weighing an average of 150 g were obtained from
Zivic-Miller, Allison Park, Pa. In each experi-
ment, 10 rats were injected intraperitoneally
with an arthropathogenic dose (60 gag of rham-
nose per g of body weight) of fragments of PG-
APS suspended in phosphate-buffered saline
(pH 7.2) (4, 8). Ten control rats were injected
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intraperitoneally with phosphate-buffered sa-
line. Rats were bled from the tail under light
ether anesthesia before injection and at periods
of 6 h to 52 days after injection. Blood was
collected on-ice, and serum was obtained 30 min
after clotting at room temperature and was then
stored at -70°C until complement analyses.
The changes in total serum hemolytic comple-
ment activity at intervals after intraperitoneal
injection of PG-APS are shown in Fig. 1. The
mean value of the hemolytic activity of the PG-
APS-injected group was compared with the
mean of the control group at each time interval.
The mean for the control group is the 100%o
value at each interval and is shown by the
horizontal line in Fig. 1. Samples of the standard
pool of rat serum were also measured at each
analysis. The range of hemolytic activity of the
control rats was 35 to 195% of the standard
serum pool. The range of the PG-APS-injected
group was 4 to 374% of the standard pool.
The decrease in hemolytic levels over the first
24 h after the PG-APS injection was expected
from the capacity of PG-APS to activate the
ACP in vitro (7). The change from depressed to
increased levels of hemolytic activity was appar-
ent at day 2 after the injection, and significantly
increased levels were maintained through day 6.
Of even greater interest was the recurrence of
significant increases at days 26 and 40 after the
single intraperitoneal injection of PG-APS (Fig.
1).
Measurement of the components of the ACP
(Fig. 2) gave results similar to the changes in
total hemolytic activity. Further analysis of
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components of the ACP showed that the levels
of C3 and factor 1D changed in an analogous
pattern, although the increase of factor 15 was
not significantly different from control values
(Fig. 2).
The increase of ACP activity after initial de-
pression has been reported in mice given multi-
ple injections of cobra venom factor (9). Infec-
tion of both malnourished and normal rats with
Staphylococcus aureus has been reported to
induce a temporary elevation in the classical
pathways and in the ACP 2 or 3 days after
infection (15). To our knowledge, the pattern of
recurrent increase of complement activity over a
period of 40 days after a single injection of a
nonviable agent has not been observed previous-
ly.
Human peripheral monocytes (21) and mouse
peritoneal macrophages (11) can synthesize the
complement components required for function-
ing of the classical pathway or the ACP. The PG-
APS fragments can persist within macrophages,
in vivo or in vitro, for prolonged periods and
stimulate the macrophages to become activated
as shown by cytotoxicity (17, 18) and enzyme
secretions (16). Therefore, we propose that the
increase in serum levels of complement activity
after injection of rats with PG-APS reflects the
stimulation of macrophages to synthesize com-
plement proteins.
The elevated levels of serum complement
activity (Fig. 1) correspond to episodes of in-
flammatory joint lesions in the model of experi-
mental arthritis induced in rats with aqueous
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FIG. 1. Hemolytic complement activity in the serum of rats injected intraperitoneally with PG-APS,
expressed as percentage of normal control serum. Each point is the mean of 10 rats compared at each time
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FIG. 2. Serum levels of ACP, factor i5, and C3 in the serum of rats injected with PG-APS, expressed as
percentage of control serum. Each point is the mean of 10 rats compared with the mean of 10 control rats by
Student's t test.
no direct evidence, as yet, that these events are
causally related, since there is no correlation
between the severity of joint disease and the
level of serum complement in individual rats.
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